Replies to post #154714 on Biotech Values

[DewDiligence]

XOMA—Uveitis is a larger market than many investors realize.

Now they seem to be taking a shot at CV. Seems like a stretch for them.

The Gevokizumab program in CV disease is funded and owned by Servier. I ascribe no value to the CV program, so if anything does become of it, it’s all upside as far as I’m concerned.